Article
A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.
PloS one - 1 Jan 2015
Gómez Carmen Elena, Perdiguero Beatriz, García-Arriaza Juan, Cepeda Victoria, Sánchez-Sorzano Carlos Óscar, Mothe Beatriz, Jiménez José Luis, Muñoz-Fernández María Ángeles, Gatell Jose M, López Bernaldo de Quirós Juan Carlos, Brander Christian, García Felipe, Esteban Mariano
Abstract excerpt
TRIAL DESIGN: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.